TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25520280

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 30 minutes per day for 7 days at bilateral points ST36, LI4, TE6, ST37 and LR3
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 80
Study: 23465062

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed after 48 hours by 400 μg oral misoprostol (Study One)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone followed after 24 hours by 400 μg sublingual misoprostol (Study Two)
Number of subjects: 0
Study: 21299448

Group type: EXPERIMENTAL
Intervention: Tailored doses of FEC chemotherapy
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Standard doses of FEC chemotherapy
Number of subjects: 1535
Study: 19922552

Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone long-acting therapy (RLAT) plus treatment-as-usual (TAU) (n = 65)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Adjunctive placebo injection plus treatment-as-usual (TAU) (n = 59)
Number of subjects: 124
Study: 17121317

Group type: EXPERIMENTAL
Intervention: Myoinositol (4 g daily) plus folic acid (400 microg daily)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 15071291

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (no ciprofloxacin)
Number of subjects: 216
Study: 11583074

Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Exposure in vivo (EXP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 31
Study: 9002079

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 30
Study: 8240880

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 3318442

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg daily
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg daily
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study: 29069400

Group type: EXPERIMENTAL
Intervention: 800 mg LCB01-0371 once or twice daily for 21 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1200 mg LCB01-0371 twice daily for 21 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27017611

Group type: EXPERIMENTAL
Intervention: Febuxostat (60 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Allopurinol (300 or 200 mg/day)
Number of subjects: 100
Study: 24323402

Group type: EXPERIMENTAL
Intervention: Image-based navigation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Individualized guides
Number of subjects: 6
Study: 24349562

Group type: EXPERIMENTAL
Intervention: Force feedback during task performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation of scientific content
Number of subjects: 0
Study: 19826944

Group type: EXPERIMENTAL
Intervention: tele-neurofeedback
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: electromyography tele-biofeedback
Number of subjects: 17

Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 17
Study: 18621575

Group type: EXPERIMENTAL
Intervention: Episodic treatment with famciclovir (125 mg twice daily for 5 days)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Suppressive treatment with famciclovir (250 mg twice daily)
Number of subjects: 384
Study: 16796221

Group type: EXPERIMENTAL
Intervention: Night work (6:30 PM to 6:30 AM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Day work (6:30 AM to 6:30 PM)
Number of subjects: 17
Study: 12631176

Group type: EXPERIMENTAL
Intervention: Amine fluoride-triclosan mouthrinse (AFT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triclosan (TRI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine solution (CHX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo solution (PLA)
Number of subjects: 15
Study: 12370320

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 0
Study: 9524008

Group type: EXPERIMENTAL
Intervention: Metoprolol (mean daily dose: 184 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined treatment (IS-5-MN + Metoprolol)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) (mean daily dose: 33 mg)
Number of subjects: 32
Study: 7974024

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy at 400 mg or 800 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy at 800 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy at 400 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (400 mg and 800 mg)
Number of subjects: 22
Study: 2564243

Group type: EXPERIMENTAL
Intervention: Aminophylline, 110 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 40
Study: 31531855

Group type: EXPERIMENTAL
Intervention: Nursery reared (NR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mother-peer-reared (MPR)
Number of subjects: 39
Study: 31641325

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 85
Study: 30650270

Group type: EXPERIMENTAL
Intervention: Liujin Runzao Concentrated Decoction (LRCD), 30 mL twice per day for 4 weeks (two courses).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy: Radix Paeoniae alba total glycosides 600 mg, twice per day.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liujin Runzao Concentrated Decoction (LRCD) + Standard therapy.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Standard therapy only).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group (LRCD + Standard therapy).
Number of subjects: 40
Study: 25755266

Group type: EXPERIMENTAL
Intervention: Debriefing sessions (4 sessions over 2 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no debriefing sessions)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Debriefing sessions
Number of subjects: 31
Study: 23245454

Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Subacute care
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study: 22359978

Group type: EXPERIMENTAL
Intervention: Metformin (3-month treatment with oral hormonal contraceptives: ethynil estradiol 35 microg plus cyproterone acetate 2 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (3-month treatment with oral hormonal contraceptives: ethynil estradiol 35 microg plus cyproterone acetate 2 mg)
Number of subjects: 66
Study: 18534405

Group type: EXPERIMENTAL
Intervention: Early tourniquet release group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Late tourniquet release group
Number of subjects: 37
Study: 16894412

Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Two-dimensional echocardiography (ECHOC)
Number of subjects: 36
Study: 15345808

Group type: EXPERIMENTAL
Intervention: CSF drainage via low-flow ventriculoperitoneal (VP) shunt
Number of subjects: 0
Study: 11329232

Group type: EXPERIMENTAL
Intervention: Dose‐intensive intravenous melphalan and autologous blood stem‐cell transplantation
Number of subjects: 65
Study: 9499666

Group type: EXPERIMENTAL
Intervention: Radiotherapy-based regimens for stage I peripheral BDHD
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Chemotherapy or combined therapy for stage II BDHD
Number of subjects: 282

Group type: COMPARATOR
Intervention: Overall survival (OS) for stage II BDHD vs stage II ADHD
Number of subjects: 282

Group type: COMPARATOR
Intervention: Age-adjusted OS for BDHD vs ADHD
Number of subjects: 282

Group type: COMPARATOR
Intervention: Prognostic factors for BDHD patients with intra-abdominal disease
Number of subjects: 282
Study: 7836876

Group type: EXPERIMENTAL
Intervention: Active cervical flexion/extension maneuvers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 16
Study: 3597148

Group type: EXPERIMENTAL
Intervention: Oral and intravesical misonidazole (MISO)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No misonidazole (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pilot study with MISO
Number of subjects: 58

Group type: COMPARATOR
Intervention: Pilot study (historical controls)
Number of subjects: 58
Study: 29016473

Group type: EXPERIMENTAL
Intervention: Low-load, higher-repetition training (LLHR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-load, lower-repetition training (HLLR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both LLHR and HLLR
Number of subjects: 15
Study: 31421816

Group type: EXPERIMENTAL
Intervention: P value threshold of .005
Number of subjects: 48

Group type: COMPARATOR
Intervention: P value threshold of .05
Number of subjects: 48
Study: 29216947

Group type: EXPERIMENTAL
Intervention: AACD‐CPR
Number of subjects: 69

Group type: COMPARATOR
Intervention: STD‐CPR
Number of subjects: 69
Study: 25733633

Group type: EXPERIMENTAL
Intervention: EGCG (600 mg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23944044

Group type: EXPERIMENTAL
Intervention: Zhennaoning capsules
Number of subjects: 254

Group type: COMPARATOR
Intervention: Yangxueqingnao granules
Number of subjects: 254
Study: 21188594

Group type: EXPERIMENTAL
Intervention: Superficial Femoral Artery (SFA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Common Femoral Artery (CFA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Closure devices (subgroup analysis)
Number of subjects: 100
Study: 19462303

Group type: EXPERIMENTAL
Intervention: Gamma-Hydroxybutyric acid (GHB) administered intravenously, initially 30 mg/kg body weight (BW) followed by 15 mg/kg BW.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clomethiazole (CLO) given orally to 12 patients in a dosage of 250 mg every 4 hours as a liquid.
Number of subjects: 26
Study: 16758078

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (8 sessions, 2 hours each, over one month)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 38
Study: 15274672

Group type: EXPERIMENTAL
Intervention: Coated pellets with pH‐dependent rapid release (EUDRAGIT FS 30D)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pellets with pH‐ and time‐based release (inner layer EUDRAGIT RL/RS 30D; outer layer EUDRAGIT FS 30D)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Uncoated immediate release tablets
Number of subjects: 12
Study: 11393182

Group type: EXPERIMENTAL
Intervention: Stage II of physiological labor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage I in primiparae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage I in multiparae
Number of subjects: 0
Study: 9587285

Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:50,000
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:80,000
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:100,000
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.8 ml of 2% lidocaine with 1:50,000
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.8 ml of 2% lidocaine with 1:80,000
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.8 ml of 2% lidocaine with 1:100,000
Number of subjects: 30
Study: 8390795

Group type: EXPERIMENTAL
Intervention: Daily antimony plus interferon-gamma (IFN-gamma) every other day (n = 10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Daily pentavalent antimony (n = 14)
Number of subjects: 24
Study: 3545618

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31385047

Group type: EXPERIMENTAL
Intervention: Covered stents (ePTFE-FEP-covered nitinol stents)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 120

Group type: COMPARATOR
Intervention: Uncovered stents
Number of subjects: 120
Study: 29956434

Group type: EXPERIMENTAL
Intervention: Premaquick
Number of subjects: 151

Group type: COMPARATOR
Intervention: Modified Bishop score
Number of subjects: 151
Study: 27051354

Group type: EXPERIMENTAL
Intervention: DHA-enriched beverage (1.16 g DHA/day) for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LPS-stimulated PBMCs
Number of subjects: 15
Study: 25751083

Group type: EXPERIMENTAL
Intervention: Residential Care Transition Module (RCTM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 17
Study: 23824870

Group type: EXPERIMENTAL
Intervention: Dietary fish oil supplementation for 3 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo supplementation for 3 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dietary fish oil supplementation following a washout period
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo following a washout period
Number of subjects: 87
Study: 20668549

Group type: EXPERIMENTAL
Intervention: EchiTAb Plus-ICP (ET-Plus) - initial dose 3 vials
Number of subjects: 400

Group type: COMPARATOR
Intervention: EchiTAb G (ET-G) - initial dose 1 vial
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: EchiTAb Plus-ICP (ET-Plus)
Number of subjects: 400

Group type: COMPARATOR
Intervention: EchiTAb G (ET-G)
Number of subjects: 400
Study: 17327787

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 23

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 23
Study: 14751423

Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20
Study: 11801808

Group type: EXPERIMENTAL
Intervention: 0.5 mg ex‐MLT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3 mg ex‐MLT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 9 mg ex‐MLT
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9580172

Group type: EXPERIMENTAL
Intervention: Antibiotic administration
Number of subjects: 733

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 733
Study: 8112231

Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg daily for children < 20 kg; 300 mg daily for others)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 84
Study: 3381783

Group type: EXPERIMENTAL
Intervention: CME intervention: tutorial plus printed materials
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CME intervention: mailed printed materials only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CME interventions (both types)
Number of subjects: 90
Study: 31453617

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (600 mg per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (600 mg cellulose per day)
Number of subjects: 12
Study: 30282392

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.9% normal saline solution (placebo)
Number of subjects: 94
Study: 26757368

Group type: COMPARATOR
Intervention: Anodal transcranial direct current stimulation (tDCS) applied to the primary somatosensory cortex (S1) over five days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham application of tDCS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS followed by functional magnetic resonance imaging (fMRI) assessments.
Number of subjects: 0
Study: 25112175

Group type: EXPERIMENTAL
Intervention: L-tryptophan, 1 g orally three times a day for up to 3 days postoperatively
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 22566583

Group type: EXPERIMENTAL
Intervention: TEAMcare intervention (multicondition collaborative treatment program)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 214
Study: 20826416

Group type: EXPERIMENTAL
Intervention: Team Functioning Survey (TFS) scales
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Revised scales from the TFS
Number of subjects: 365
Study: 17883296

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 100 mg administered 2 hours prior to ERCP
Number of subjects: 150

Group type: COMPARATOR
Intervention: Rectal glycerin (control group)
Number of subjects: 150
Study: 16631259

Group type: EXPERIMENTAL
Intervention: CD24 Ala/Val polymorphism
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Control group (unrelated and family‐based controls)
Number of subjects: 2348
Study: 14597376

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine in children without older siblings attending day-care at 24 months
Number of subjects: 0
Study: 10561226

Group type: EXPERIMENTAL
Intervention: Standard alloBMT
Number of subjects: 840

Group type: COMPARATOR
Intervention: IFNalpha therapy
Number of subjects: 840

Group type: COMPARATOR
Intervention: Conventional chemotherapy (CHT)
Number of subjects: 840
Study: 8741040

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTXF) 5 mg/kg per hour for 6 hours for 3 successive days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTXF)
Number of subjects: 29
Study: 1841918

Group type: EXPERIMENTAL
Intervention: Heart rate maintained at 100-110 beats/min (Group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Heart rate maintained at 90-100% of anaerobic threshold (Group B)
Number of subjects: 105
Study: 7116299

Group type: EXPERIMENTAL
Intervention: Oral melphalan (0.15 mg/kg/day for seven days, followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Number of subjects: 361

Group type: COMPARATOR
Intervention: BCNU (150 mg/m2 intravenously every six weeks) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Number of subjects: 361

Group type: COMPARATOR
Intervention: CCNU (100 mg/m2 orally every six weeks) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Vincristine (1 mg/m2) + Prednisone (0.6 mg/kg for seven days) every two months (added at week 22)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Good-risk patients treated with oral melphalan
Number of subjects: 361
Study: 30864815

Group type: EXPERIMENTAL
Intervention: Outdoor nighttime wind turbine noise (WTN) exposure
Number of subjects: 583968

Group type: EXPERIMENTAL
Intervention: Outdoor nighttime wind turbine noise (WTN) exposure (highest exposure group)
Number of subjects: 583968

Group type: EXPERIMENTAL
Intervention: Indoor nighttime low-frequency wind turbine noise (LF WTN) exposure (highest exposure group)
Number of subjects: 583968
Study: 29048765

Group type: EXPERIMENTAL
Intervention: Ageratum conyzoides extract at a dose of 250 mg/d, q.d. for 12 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 24633440

Group type: EXPERIMENTAL
Intervention: Transcricoid lignocaine injection
Number of subjects: 0
Study: 24439313

Group type: EXPERIMENTAL
Intervention: Chemotherapy (multidrug for at least four courses recommended)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 162
Study: 22625863

Group type: EXPERIMENTAL
Intervention: ProTaper (PT) files used in reciprocating motion
Number of subjects: 60

Group type: COMPARATOR
Intervention: ProTaper (PT) files used in continuous rotary motion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Twisted Files (TF) used in continuous rotary motion
Number of subjects: 60
Study: 20021401

Group type: EXPERIMENTAL
Intervention: Low frequency transcutaneous sensory nerve stimulation (LF‐SNS) for 5 minutes, twice daily for up to 12 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham nerve stimulation
Number of subjects: 29
Study: 21179755

Group type: EXPERIMENTAL
Intervention: Nutritional supplement designed for high altitude
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stir-fried flour supplement (Control)
Number of subjects: 40
Study: 13680141

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN), 10 mg daily
Number of subjects: 134

Group type: COMPARATOR
Intervention: Alfacalcidol (AC), 1 microg daily
Number of subjects: 134
Study: 11481083

Group type: EXPERIMENTAL
Intervention: Paclitaxel treatment
Number of subjects: 6
Study: 10424695

Group type: EXPERIMENTAL
Intervention: Right hemisphere for spatial judgments
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Left hemisphere for identity judgments
Number of subjects: 2
Study: 7596131

Group type: EXPERIMENTAL
Intervention: DL-nebivolol 5 mg once daily for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: D-nebivolol 2.5 mg once daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2248813

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.1 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ranitidine 2 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.1 mg kg‐1 with ranitidine 2 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: no premedication
Number of subjects: 40